Bellicum announces reverse stock split

Houston, feb. 05, 2020 (globe newswire) -- bellicum pharmaceuticals, inc. (nasdaq: blcm) (“bellicum” or the “company”), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that the company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-10. the effective time of the reverse stock split will be 5 p.m. et on february 5, 2020. the company’s common stock will begin trading on a split-adjusted basis commencing upon market open on february 6, 2020.
BLCM Ratings Summary
BLCM Quant Ranking